Search results
Study Elucidates Skin Signs of VEXAS Syndrome
Medscape· 5 days agoSkin manifestations are common in the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome and present early in the disease course....
Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial
Medscape· 5 days agoResults from the phase 3 SELECT-GCA study showed that the Janus kinase (JAK) inhibitor upadacitinib...
7 signs your mystery rash is something more serious
TODAY via Yahoo News· 5 days agoHere are some potential signs. 1. Fever or pain in addition to a rash. These could indicate an infection or allergic reaction. 2. Bruise-like marks that...
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
Morningstar· 7 days agoData Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA® and Progress in Addressing Sjögren's Disease THOUSAND OAKS, Calif., June 12, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today ...
Toddler waits five hours for scan after suffering rare deadly condition
Daily Mirror· 3 days agoA toddler had to wait more than five hours for a scan after suffering an incredibly rare stroke...
Research Analysts Set Expectations for argenx SE’s Q2 2025 Earnings (NASDAQ:ARGX)
ETF DAILY NEWS· 20 hours agoargenx SE (NASDAQ:ARGX – Free Report) – Equities research analysts at Wedbush lowered their Q2 2025 earnings per share (EPS) estimates for argenx in a research note issued to investors on Monday ...
Q32 Bio (NASDAQ:QTTB) Receives New Coverage from Analysts at Guggenheim
ETF DAILY NEWS· 23 hours agoGuggenheim assumed coverage on shares of Q32 Bio (NASDAQ:QTTB – Free Report) in a research report released on Monday, Marketbeat reports. The firm issued a buy rating and a $100.00 target price ...
John Andersen: Fauci deserves credit for mitigating COVID-19 spread
The Chippewa Herald· 4 days agoFather’s Day is tomorrow. Followed by the summer solstice at 3:50 p.m. Thursday.
argenx’s (ARGX) “Buy” Rating Reaffirmed at HC Wainwright
ETF DAILY NEWS· 5 days agoHC Wainwright’s price objective would suggest a potential upside of 15.36% from the stock’s current price. Other research analysts have also issued research reports about the company. JMP Securities ...